Drug Target Review

JANUARY 23, 2024

What innovative approaches and technologies are anticipated to reshape immuno-oncology treatments in 2024? Immuno-oncology, notably through checkpoint inhibitors, has significantly reshaped cancer treatment over the past decade.

Treatment 122

Treatment Immune Response Vaccine Therapies 122

Drug Discovery World

FEBRUARY 28, 2024

Lu Rahman selects some of the year’s interesting and noteworthy advances in cancer research drug discovery and development. In the UK, according to Cancer Research UK, around 167,000 people die from cancer in the UK each year. Research into new drugs and therapeutics is on-going and is helping drive mortality rates down.

Drug Development 162

Drug Development Research Clinical Trials Drugs 162

Broad Institute

JULY 11, 2024

Targeted drug treatment leads tumor cells to imitate viral infection By Ari Navetta July 11, 2024 Breadcrumb Home Targeted drug treatment leads tumor cells to imitate viral infection Exploiting "viral mimicry," mIDH1 inhibitors trick tumors into thinking they are infected with a virus.

Treatment 72

Treatment Immune Response Virus Drugs 72

Drug Discovery World

OCTOBER 7, 2022

Researchers from King’s College London and The Institute of Cancer Research, London, have performed a deep dive into the different immune markers within tumour tissue and blood samples of early breast cancer patients whose cancer failed to respond to chemotherapy given to them prior to surgery.

Research 130

Research Immune Response Bioinformatics Treatment 130

Drug Discovery World

AUGUST 6, 2024

Circular RNAs (circRNAs) have “remarkable potential” to improve cancer treatment and patient outcomes within the next five to 10 years, according to a new study by Flinders University in Australia. We’ve also discovered that high levels of circRNAs in certain people can cause mutations in their DNA which results in leukaemia.”

Therapies 147

Therapies RNA Immune Response DNA 147

Drug Discovery World

AUGUST 7, 2023

Evox Therapeutics has agreed a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) in New York, NY, US. The collaboration will work on developing exosome-encapsulated AAV (exoAAV) vectors as a novel gene delivery technology aimed at improving treatments for heart disease.

Therapies 130

Therapies Disease Research Immune Response 130

Drug Discovery World

SEPTEMBER 9, 2022

Researchers have found that RP2 – a modified version of the herpes simplex virus – showed signs of effectiveness in a quarter of patients with a range of advanced cancers. One patient with salivary gland cancer saw his tumour disappear completely and remains free of cancer 15 months after starting treatment.

Virus 130

Virus Research Immune Response Engineering 130

Drug Discovery World

MAY 2, 2024

A study led by the University of Oxford has successfully investigated human immunity against Covid-19 in people who already have antibodies, with the aim of advancing future vaccines and treatments. The data from this COVCHIM01 study showed durable immunity post-infection/vaccination against the original Covid-19 virus.

Vaccine 147

Vaccine Immune Response Virus Treatment 147

Drug Target Review

JANUARY 15, 2024

Our innate immune system evolved to clear genetically diverse pathogens and limit host toxicity, raising the possibility that it can produce similar effects in cancer. Could you provide insights into the driving factors behind exploring novel treatments for cancer types? What aspects prompted this research direction?

Treatment 105

Treatment Immune Response Clinical Trials Therapies 105

Olympian Clinical Research

MAY 6, 2024

The journey toward effective treatments has been long and evolving, with recent breakthroughs offering new hope to those living with this challenging condition. From Coal Tar to Biologics: A Historical Perspective The history of psoriasis treatment is as old as the condition itself, with records dating back to ancient times.

Treatment 52

Treatment Small Molecule Immune Response Clinical Research 52

Drug Discovery World

MARCH 4, 2024

In an early phase clinical trial, a combination of antibody-based medications targeting the immune system generated promising safety data and anti-tumour activity in individuals with advanced cancer. Both medications tested in the trial support immune responses against tumour cells. Various dosing schedules of CS1002 (0.3,

Therapies 289

Therapies Immune Response Clinical Trials Trials 289

Drug Discovery World

APRIL 9, 2024

A study by researchers at the UCLA Health Jonsson Comprehensive Cancer Center in the US suggests that injecting engineered dendritic cells directly into cancerous lung tumours can help promote a stronger immune response.

Engineering 130

Engineering Therapies Immune Response Treatment 130

Drug Discovery World

JULY 12, 2023

Scientists investigating potential drugs to improve recovery from spinal cord injury have uncovered a promising route to new treatments. Researchers tested more than 1000 potential drugs and identified that an existing one – cimetidine – improved spinal repair in zebrafish.

Immune Response 130

Immune Response Drugs Regulations Treatment 130

Olympian Clinical Research

NOVEMBER 30, 2023

Vitiligo, characterized by the loss of skin pigment and the formation of white patches, has been a subject of medical intrigue and research for decades. The exact cause of vitiligo is still under investigation, with factors like genetics , autoimmune responses, and environmental triggers all playing potential roles.

Treatment 52

Treatment Clinical Research Clinical Trials Immune Response 52

Drug Discovery World

MAY 23, 2024

The three-year survival rate for children with high-grade gliomas, without further complications, is only 11-22%, and the currently available treatments, radiotherapy and chemotherapy, can harm the child’s developing brain. The researchers will use a genetically engineered herpes simplex virus type 1 to eliminate cancer cells.

Virus 147

Virus Immune Response Vaccine Engineering 147

Drug Target Review

JUNE 9, 2023

This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, unveils some ground-breaking research on T- cell therapy for cancer , which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.

Treatment 105

Treatment Packaging Clinical Research Therapies 105

Drug Discovery World

APRIL 12, 2024

The cancer research news has been coming thick and fast from the American Association of Cancer Research (AACR) Annual Meeting in San Diego this week, so our Friday round-up focuses on drug discovery in oncology. News round-up for 8-12 April by DDW Digital Content Editor Diana Spencer.

Immune Response 130

Immune Response Engineering Drugs Therapies 130

Science Daily: Pharmacology News

OCTOBER 18, 2023

Glioblastoma (GBM), an aggressive brain cancer, is notoriously resistant to treatment, with recurrent GBM associated with survival of less than 10 months.

Therapies 74

Therapies Immune Response Research Virus 74

Drug Discovery World

MAY 28, 2024

Researchers from The University of Queensland and the Queensland Children’s Hospital (QCH) have successfully tested the first-in-class drug in mice. A new drug could prevent sepsis-related organ failure and death by restoring the health of a patient’s blood vessels.

Immune Response 147

Immune Response Hospitals Drugs Clinical Trials 147

Broad Institute

MARCH 20, 2024

doi: 10.1038/s41590-024-01792-2 (2024) Scientists used a microscope to visualize an immunity hub (yellow and green) in human lung tumor tissue (blue). doi: 10.1038/s41590-024-01792-2 (2024) Scientists used a microscope to visualize an immunity hub (yellow and green) in human lung tumor tissue (blue). Nature Immunology.

Immune Response 131

Immune Response Hospitals Research Treatment 131

Drug Discovery World

MARCH 12, 2024

Elicera Therapeutics will make parts of its technology iTANK available to a medical oncologist and researcher at the undisclosed US cancer centre, whose investigation focuses on the development of novel immunotherapies. The iTANK technology platform has been developed for arming and enhancing CAR T-cells for the treatment of solid tumours.

Therapies 130

Therapies Immune Response Licensing Licensing 130

Drug Discovery World

MARCH 17, 2023

Researchers have shown for the first time that malfunctioning behaviour of a type of immune cell is linked to specific symptoms of Long Covid. Normally functioning monocytes, made in the bone marrow, would travel through the blood to the lungs where they surround and kill the virus and boost the immune response.

Immune Response 130

Immune Response Drugs Vaccine Virus 130

Drug Discovery World

JULY 26, 2023

A Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working. The drug, MOv18 IgE, was developed by researchers at King’s College London.

Clinical Trials 130

Clinical Trials Immune Response Drugs Trials 130

The Pharma Data

JULY 29, 2021

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Kumquat Biosciences today announced an exclusive collaboration focused on the discovery, development and commercialization of potential novel small molecules that stimulate tumor-specific immune responses.

Small Molecule 52

Small Molecule Immune Response Research Laboratories Laboratories 52

Drug Target Review

FEBRUARY 21, 2024

Stem cell transplants primarily help the immune response through the “graft-versus-leukaemia effect,” and we have to manage the “graft versus host effect.” This involves the use of CAR-T cell products derived from donor T cells, hence the term “off the shelf,” making it easier to standardise treatments.

Therapies 64

Therapies Treatment FDA Approval Vaccine 64

Drug Discovery World

SEPTEMBER 7, 2023

Researchers have discovered a new avenue of cell death in Alzheimer’s disease and vascular dementia. This finding will open new avenues in drug discovery for Alzheimer’s disease as potential new treatments could focus on reducing microglial degeneration in the brain. When myelin is damaged, microglia swarm in to clear the debris.

Immune Response 162

Immune Response Laboratories Drugs Science 162

Drug Discovery World

NOVEMBER 17, 2022

Researchers have identified 35 genes associated with long-term Lyme disease that could potentially be used as biomarkers to diagnose patients with the condition. . As part of the study, RNA sequencing was conducted using blood samples from 152 patients with symptoms of post-treatment Lyme disease to measure their immune response. .

Disease 130

Disease RNA Immune Response Bioinformatics 130

Drug Discovery World

OCTOBER 10, 2023

Read more: Preclinical study proves antidepressant effects of drug Psychedelic-based drug options Later the same month, Cybin announced it had completed dosing in Cohort 5 of a Phase II trial evaluating CYB003, an investigational proprietary deuterated analog of psilocybin for the potential treatment of major depressive disorder (MDD).

Immune Response 147

Immune Response Drugs FDA Approval DNA 147

Drug Discovery World

NOVEMBER 22, 2022

Cancer is supported by complex ecosystems within the body which can be disrupted by cutting-edge new treatments and cures, cancer researchers have concluded. . The five-year research strategy aims to unravel cancer’s ecosystem, diagnose cancer better and earlier, target cancer’s weaknesses and treat cancer more precisely. .

Immune Response 130

Immune Response Research Treatment Drugs 130

Drug Discovery World

MARCH 19, 2024

The company plans to submit an Investigational New Drug (IND) application to the FDA for AT-108 by 2026, expand and reinforce its research and development team, and fuel new reprogramming modalities and delivery platforms to strengthen the pipeline.

Immune Response 130

Immune Response Packaging Therapies FDA 130

Drug Discovery World

SEPTEMBER 28, 2023

The company demonstrated that resminostat is well tolerated and can inhibit tumour growth and proliferation, cause tumour regression, and strengthen the body’s immune response to cancer in the RESMAIN study. Currently, CTCL is incurable and treatment options for advanced-stage CTCL are limited.

Therapies 130

Therapies Immune Response FDA Treatment 130

Drug Discovery World

AUGUST 16, 2023

Researchers have shown that a novel antibody has greater activity and potentially fewer side effects than existing biological therapies for conditions such as rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease (IBD).

Immune Response 130

Immune Response Disease Therapies Treatment 130

Drug Target Review

MARCH 1, 2024

Can you elaborate on the key findings of the preclinical data published in Cancer Immunology Research? How significant are the results in terms of advancing TCR-T cell therapy and AMP immunotherapy for the treatment of solid tumours? It may also overcome resistance mechanisms developed by tumours to evade the immune response over time.

Immune Response 105

Immune Response Vaccine Therapies Small Molecule 105

Drug Discovery World

DECEMBER 16, 2022

A Phase I clinical study of STORM’s potential first-in-class candidate STC-15, an orally-bioavailable, highly selective METTL3 inhibitor, commenced treatment of cancer patients with solid tumours in November 2022. STC-15 triggers both direct cytotoxic and immune response-based efficacy mechanisms in solid tumour and leukaemia models.

RNA 130

RNA Immune Response Small Molecule Therapies 130

Olympian Clinical Research

NOVEMBER 9, 2022

Therefore, if you or a loved one is dealing with this rare condition, it’s essential to educate yourself about the condition and its potential treatments. This condition is thought to result from the immune system mistakenly attacking a thin layer of tissue below the outer layer of your skin.

Treatment 52

Treatment Clinical Research Immune Response Therapies 52

Drug Discovery World

MARCH 30, 2023

This breakthrough marks the first of its kind in China and represents a significant milestone in innovative drug discovery pathways for cancer treatment. According to data and analytics company Globaldata, the approval of LK101 injection sets the stage for exciting developments in the field.

Vaccine 130

Vaccine Regulations Trials Immune Response 130

Drug Discovery World

JULY 25, 2023

These include two antibodies for modulating immune responses in cancer and autoimmunity, which are being advanced through pharmaceutical partnerships with Novartis and GlaxoSmithKline. DDW Volume 24 – Issue 2, Spring 2023 – Global Cancer Research Guide Biography: Frédéric Triebel, MD PhD, founded Immutep in 2001.

Immune Response 246

Immune Response Therapies Vaccine Production 246